ESA product use, by DOPPS country and cross-section

  Epoetin only Darbepoetin only Mircera only Other
N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd %
DOPPS Country DOPPS Cross-section 150 63.5% 91 36.5% 0 0.0% 0 0.0%
AusNZ D4(2010)
D4(2011) 151 50.6% 152 45.2% 0 0.0% 22 4.3%
Belgium D4(2010) 152 42.3% 180 42.5% 63 15.2% 0 0.0%
D4(2011) 101 29.3% 198 48.7% 95 22.0% 0 0.0%
Canada D4(2010) 134 37.7% 152 62.3% 0 0.0% 0 0.0%
D4(2011) 170 34.9% 229 65.1% 0 0.0% 0 0.0%
France D4(2010) 57 17.6% 184 57.7% 58 24.7% 0 0.0%
D4(2011) 88 21.5% 214 55.2% 71 23.3% 0 0.0%
Germany D4(2010) 282 58.3% 152 29.4% 36 7.7% 28 4.6%
D4(2011) 280 54.7% 152 28.7% 41 8.3% 42 8.3%
Italy D4(2010) 250 56.6% 140 33.2% 42 10.3% 0 0.0%
D4(2011) 242 53.4% 155 32.8% 56 13.0% 2 0.8%
Japan D4(2010) 630 48.0% 644 51.4% 0 0.0% 5 0.6%
D4(2011) 624 46.7% 639 48.2% 0 0.0% 67 5.0%
Spain D4(2010) 279 52.3% 178 33.6% 64 13.5% 4 0.5%
D4(2011) 241 49.7% 143 31.6% 72 18.2% 3 0.6%
Sweden D4(2010) 252 66.1% 122 32.9% 3 1.0% 0 0.0%
D4(2011) 253 65.2% 147 33.2% 7 1.6% 0 0.0%
UK D4(2010) 114 45.5% 164 46.9% 29 7.6% 0 0.0%
D4(2011) 128 40.8% 168 44.4% 72 13.8% 2 1.0%
US D4(2010) 2,665 94.6% 120 5.4% 0 0.0% 0 0.0%
D4(2011) 2,785 94.1% 263 5.9% 0 0.0% 0 0.0%

Medications reported as prescribed (not necessarily taken) in previous three months, among treated patients

Please see additional methodological information in the Data Sources and Methods section.